Stock Price & Analysis

Based on the provided data and current market context, here's a concise analysis of COR stock:

Technical Analysis

Recent Performance & Valuation

Market Position & Outlook

• Cencora (COR) has shown resilient performance with a 5.7% rise over the past year
• The company maintains a strong position as one of the world's largest pharmaceutical service companies, focusing on drug distribution and related services
• Recent analyst actions are positive:
  • BofA raised price target to $270 from $260
  • Leerink increased target to $301 from $287

Growth & Financial Strength

• Consensus EPS estimate for fiscal 2025 has moved up by 1.3% to $15.29 over the past 30 days
• Company demonstrates consistent earnings performance with a trailing four-quarter earnings surprise of 4.94%
• Strong positioning in pharmaceutical industry enables early-stage partnerships with pharmaceutical companies

Key Catalysts

• Growing presence in pharmaceutical distribution network
• Extensive worldwide distribution capabilities
• Strong track record in commercialization services
• Solid integration capabilities with pharmaceutical partners

Recommendation Based on the positive analyst revisions, strong fundamental positioning, and growth outlook, COR stock appears to be a BUY at current levels. The company's essential role in pharmaceutical distribution and consistent execution provide a stable foundation for continued growth.

Based on the provided data, here is the price prediction for COR stock in 2025:

COR stock is expected to reach $282-307 by end of 2025, representing a 15.8-26% upside from current levels, driven by strong healthcare distribution business fundamentals and continued earnings growth. The company's Q4 2024 earnings beat and raised FY2025 guidance to $15.40 EPS (midpoint) signals management's confidence in sustained growth momentum.

Key Growth Drivers:

• Strong healthcare distribution business with rising utilization and specialty medications demand expected through FY2025
• Consensus EPS growth forecast of 11.7% for FY2025
• Solid earnings surprise history, beating estimates in last 4 quarters

Analyst Consensus:

• Strong Buy rating from 11 out of 15 analysts, with 4 Hold ratings
• Mean price target: $282.14 (15.8% upside)
• Street-high target: $307 (26% upside)
• Recent upgrades: Baird ($307), BofA ($270), Leerink ($301) [1, 2]

The S1 support level for COR Stock is $243.08 ,The R1 resistant level for COR Stock is $256.34.

As of the end of day on 2025-03-06, the price of COR Stock was $252.5.

The target price for COR Stock according to analyst rating is 281.10, with the highest price target at 308.00 and the lowest at 251.00. Analysts have a Moderate Buy rating on COR Stock overall.

The market cap of COR is $49.2B.

Based on the provided data and context, here is a comprehensive analysis of COR's valuation:

Current Market Position: COR is currently trading at $244.61, showing a modest 5.9% gain over the past 52 weeks, significantly underperforming the S&P 500's 20.5% rally during the same period.

Valuation Analysis:

• The stock is currently trading at a GARP (Growth at a Reasonable Price) level, indicating balanced valuation metrics relative to its growth prospects.
• Recent Q4 earnings exceeded Wall Street's expectations with revenue increasing 12.8% year-over-year to $81.49 billion.
• Management raised full-year adjusted EPS guidance by 3% to $15.40 at the midpoint.

Analyst Sentiment:

• Strong consensus among analysts with 11 "Strong Buy" ratings and 4 "Hold" ratings.
• Recent price target updates:
  • BofA raised target to $270 from $260 (Neutral rating)
  • Baird raised target to $307 from $305 (Outperform rating)
  • Mean price target of $282.14 suggests 15.8% upside potential

Conclusion: Based on the comprehensive analysis, COR appears fairly valued at current levels considering:

1. Strong earnings growth and raised guidance
2. Positive analyst sentiment with significant upside potential
3. Solid business fundamentals despite market underperformance
4. Trading at reasonable multiples relative to growth prospects
5. Strong market position in pharmaceutical services sector

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company is focused on improving the lives of people and animals around the world. It is engaged in the delivery of pharmaceuticals, healthcare products, and solutions. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

Based on the provided data, here is a price prediction for COR (Cencora Inc.) stock by 2030:

Cencora's stock is projected to reach $320-350 by 2030, driven by its strong market position in pharmaceutical distribution and consistent earnings growth. The company's recent 12.8% revenue growth and strategic focus on pharmaceutical services partnerships indicate sustained long-term potential. Wall Street analysts maintain a "Strong Buy" consensus with a near-term price target of $282, suggesting a solid growth trajectory.

COR has a total of 42000 employees.